Stent Market By Product Type (Vascular {Coronary Stents, Peripheral Stents [Iliac Artery Stents, Femoral Artery Stents, Carotid Artery Stents, Renal Artery Stents, Other Peripheral Stents], Neurovascular Stents [Intracranial Stents, Flow Diverters]}, Non-vascular Stents {Gastrointestinal Stents [Biliary, Duodenal, Colonic, Pancreatic, Esophageal Stents], Pulmonary Stents [Silicone Airway, Metallic Airway, Urological Stents, Others]), By Material (Metal, Polymer, Combination, Bioabsorbable), By End-user (Hospitals, Ambulatory Surgical Centers, Specialized Clinics, Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Stent market accounted for USD 14.3 Billion in 2024 and is expected to reach USD 23.7 Billion by 2035, growing at a CAGR of around 4.7% between 2025 and 2035. The stent market is defined as the business of designing, producing, and merchandising stents, which are implants employed to open blockages in blood vessels, the urinary tract, and other organs. Stents are widely applied in surgery and treatment of cardiovascular diseases, diseases of the urinary system, and other related disorders.

The market breaks it down into coronary, peripheral, and drug-eluting stents used in hospitals, clinics, and surgical centers. Market development drivers include a rise in the geriatric population, a rise in the incidences of lifestyle diseases, and improvement in stent innovation.

Report Scope:

Market Dynamics

Growing prevalence of cardiovascular and chronic diseases worldwide

Cardiovascular diseases (CVDs) are one of the leading causes of death in the world today and their rates are gradually rising due to among other reasons; aging populations, unsustainable lifestyles, and increasing rates of hypertension, diabetes, and obesity. CVD accounts for approximately 31% of all global deaths, more specifically for 17.9 million deaths per WHO.

Increasing incidence of coronary artery diseases and other vascular diseases due to the concept of early aging in the global inhabitants, especially in North America and Europe will create more demand for stents. Also, lifestyle diseases are on the rise in developing regions such as Asia-Pacific, which will also propel the requirement to implant a stent. As CVDs continue to be significant causes of morbidity and mortality, stenting procedures function as a primary method of managing and treating conditions under high healthcare demand worldwide.

Advancements in stent technology and materials enhancing treatment options

Stent development and its materials used have enhanced stenting procedures to increase success rates in cases of restenosis or thrombosis, or problems resulting from new implantation ever since drugs were incorporated in stents known as drug-eluting stents DES which ensures that medication is released and does not re-narrow the artery.

Also, advanced technologies in biodegradable, stents that can disappear from the patient's body over time are helping in minimizing complications in the future after the stenting procedure is done. Bioabsorbable polymers, cobalt-chromium, and platinum-chromium alloys have increased stent sturdiness or flexibility and biocompatibility, shortening patient rehabilitation time and adverse effects. Such technological advancements are estimated to help broaden the treatment methodology and hence spur the growth of the stent industry.

High Cost of Stent Procedures and Materials Limiting Accessibility

One of the most important reasons affecting the availability of stent procedures and materials is the high cost of conducting the procedures and the purchase of materials. This cost extends beyond the cost of the stent to include the procedures in conjunction with the stent installation including imaging hospital stays and additional care post-surgery. Drug-eluting stents are more sophisticated compared to ordinary stents and are effective in preventing restenosis, but their cost is high, and therefore they remain unavailable in nations with constrained health budgets.

However, based on the number of stents used, insurance costs can be a limiting factor for patients, especially those in the elderly population or those having chronic illnesses who will need several sets of stents in their lifetime. This issue has averted more attention to establishing low-cost substitutes and enhancing the delivery of stent treatments to unserved areas.

Growing Demand for Stents in Elderly Population with Chronic Conditions

The population of elderly people is rising rapidly in the entire world and with it the rates of chronic diseases which include cardiovascular diseases, diabetes, and hypertension and they all require stenting. Some categories of patients suffer from arterial blockages and other vascular diseases more frequently, and when they do, they tend to need stent implantation for the unblocking of the blood vessels and to prevent the appearance of new complications. With the increase in life expectancy, the population needs medical equipment such as stents that will always be demanded on the market.

Growing cases of elderly people with long-term illnesses also act as a driving factor in the stent market since more focus is paid to the treatment of long-term illnesses that could benefit from stent technologies. Further, as healthcare organizations continue to grow and advance, the availability of stent treatments is also likely to rise thus putting continuous demand forward. Also, technological developments that enhance the material from which the stent is made, or its construction increase their efficiency and their utilization in a diverse of vascular disorders.

Growing Healthcare Infrastructure in Emerging Markets Expands Stent Adoption

Increased awareness of emerging regions' healthcare sectors also contributes to increased use of stents through better availability of enhanced medical technologies and sector treatments. Since such regions enhance the quality of their hospitals and equipment, stent services are promoted particularly in countries with high cardiovascular prevalence. Increased hospitals as well as a growing number of trained medical workers drive the need for stents.

Furthermore, more funds from the government’s healthcare budget are being used to ensure that these vital gadgets are purchased. The heightened awareness created by such diseases and their treatment also favors the use of stents. Modernization of emerging markets has opened a huge scope for growing the market in stent manufacturers due to the increasing healthcare infrastructure.

Industry Experts Opinion

“Many medical procedures, particularly those involving cardiac intervention, require stents. These thin, mesh-like tubes help treat clogged or constricted arteries because they keep the blood vessel open and physically stable.”

• Dr. Birmal Chhajer, former consultant at AIIMS and Director, SAAOL Heart Centre, New Delhi

Segment Analysis

Based on product type, the stent market is classified into vascular stents and non-vascular stents depending on the requirements of the medical application. The global vascular stents market is currently leading the market and is divided into coronary stents and peripheral stents. Coronary stents are used in coronary artery diseases; peripheral stents are used in diseases of arteries such as iliac, femoral, carotid, and renal arteries. Intracranial stents and flow diverters are used for the treatment of cerebral aneurysms and other neurovascular disorders. There are primarily non-vascular stents like gastrointestinal stents and pulmonary stents and others like urological stents etc., Gastrointestinal stents can be biliary stents, duodenal stents, esophageal stents, and many more.

Based on the material used in their manufacture, stents are divided into metal stents, polymer-based stents, combination stents, and bioabsorbable stents. Most are made from stainless steel or cobalt-chromium alloys because their strength and durability are well-liked. The increased flexibility and ease of implantation are driving polymer stents to be increasingly popular in applications outside of the vasculature. Combination stents have both metal and polymer parts and possess better overall performance parameters than pure metal strut designs. Bioabsorbable stents are a new and fast-growing segment because they are self-retrievable after serving their intended use or as observation indicates restenosis may be imminent, while they are preferred for their perceived capacity to enhance patient benefits across coronary and peripheral artery applications. All these material-based advances remain with the market and meet individual patient requirements in different uses.

Regional Analysis

North America continues to dominate the stents market because of well-developed technological infrastructure, high spending on healthcare products, and constant innovation in the field of medical devices. The region has a long-standing corporate patient base with a baseline population suffering from cardiovascular diseases and other major chronic disease conditions that can require intervention with stenting. In the United States, it is primarily because large medical technology companies such as Abbott Labs, Medtronic, and Boston Scientific offer stent technologies. Also, the increase in the number of minimally invasive surgeries and the rising demand for drug-eluting stents (DES) over bare metal stents promotes market growth. North America also spearheads the required research and development (R&D) to support advanced stent development.

The Asia-Pacific region is the fastest-growing stent market due to rising enhancements in healthcare infrastructure, a growing elderly population, and increasing cardiovascular diseases. Developing countries such as China, India, and Japan are experiencing these demands because people have better access to health facilities and more people have middle income power to afford these things. Moreover, there is huge investment by government and global players to develop and expand health care facilities as well as technological enhancements in terms of medical facilities are releasing high percentage growth to the market. Newly developed awareness about cardiac health and the global trend toward the least invasive procedures also complement stent procedures more, thereby becoming a crucial market in Asia-Pacific.

Competitive Landscape

The global stent market consists of several big key players that restrict market competition and hold major market share attributed to their advanced technologies and broad existing product range, such as Abbott Laboratories, Boston Scientific, Medtronic, and Cordis. Such corporations offer a wide variety of stents that include drug-eluting stents, bioabsorbable stents, and coronary stents which major in preventing restenosis and enhancing patient results. The existing competition also comes from Braun, Terumo Corporation, and Biotronik, which offers superior stent products for more specific market segments such as peripheral and carotid artery diseases.

New material development for instance biodegradable stents is another area companies are putting much investment in, while cooperation is another significant aspect for growth. It means that the competitive advantage in this market is associated with the acquisition of a leading position in terms of technological profile, obtaining of authorizations, presence at the key distribution channels, as well as growing concern about complications and patient safety.

Stent Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In Nov 2024, Mumbai-based stent manufacturer Sahajanand Medical Technologies planned to raise ₹2,000 crore through an IPO, aiming to fuel global growth. Majority stakeholders Morgan Stanley PE Asia and Samara Capital were expected to partially exit their investment, while the company sought to strengthen its leadership in India's drug-eluting stent market.
• In Oct 2024, India-based drug makers Cipla and Alkem Laboratories Limited are reported to have been edged ahead of competitors in the race to buy a controlling stake in cardiac stent manufacturer Sahajanand Medical Technologies (SMT). This came after KKR, TPG Capital, as well as Apax Partners, displayed interest before pulling out as competitors in the private equity business.
• In June 2024, Royal Philips, a global leader in health technology,  announced the first implant of the Duo Venous Stent System, an implantable medical device indicated to treat symptomatic venous outflow obstruction in patients with chronic venous insufficiency (CVI), following premarket approval (PMA) from the U.S. Food and Drug Association (FDA).

Report Coverage:

By Product Type

• Vascular
  • Coronary Stents
  • Peripheral Stents
    • Iliac Artery Stents
    • Femoral Artery Stents
    • Carotid Artery Stents
    • Renal Artery Stents
    • Other Peripheral Stents
  • Neurovascular Stents
    • Intracranial Stents
    • Flow Diverters

• Non-vascular Stents
  • Gastrointestinal Stents
    • Biliary
    • Duodenal
    • Colonic
    • Pancreatic
    • Esophageal Stents
  • Pulmonary Stents
    • Silicone Airway
    • Metallic Airway
    • Urological Stents
    • Others

By Material                        

• Metal
• Polymer
• Combination
• Bioabsorbable

By End-user

• Hospitals
• Ambulatory Surgical Centers
• Specialized Clinics
• Other

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Abbott Laboratories
• Boston Scientific Corporation
• Medtronic
• Cordis Corporation
• B. Braun Melsungen
• Terumo Corporation
• Cook Medical
• Merit Medical Systems, Inc.
• STENTYS S.A.
• Royal Philips
• Biotronik
• Intuitive Surgical
• Asahi Intecc Co., Ltd.
• Medi-Globe
• Lepu Medical Technology
• Stryker Corporation
• Zimmer Biomet

Frequently Asked Questions (FAQs)